OncoSil Medical Ltd OSL
ASX · Australia · Health Technology
AUD 0.8200-0.05 (-5.20%)
Market closed· · AUD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · AUD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Proceeds are earmarked for the commercial rollout of the OncoSil device in Australia and the US.
OncoSil Medical Ltd (ASX:OSL, OTC:OCMLF) has secured US Food and Drug Administration (FDA) approval for its OncoSil™ targeted radiation device to treat distal cholangiocarcinoma (dCCA), giving the company US marketing authorisation and opening an estimated A$80 million annual addressable...
The approval is expected to drive increased clinical adoption and support applications for regulatory approval in other markets.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.